Kolon TissueGene starts Phase III clinical trial for ‘Invossa’

Published: 2018-07-10 16:29:00
Updated: 2018-07-11 15:39:24

Kolon TissueGene(CEO Bum-Seop Lee & Woo-Seok Lee) announced on the 6th that they acquired the Chemistry, Manufacturing and Controls(CMC) from the U.S. FDA and would start a Phase III clinical trial in the U.S.

Kolon TissueGene acquired approval of the Phase III clinical trial on May 2015 and has...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean





TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.